Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Senior Associate

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Perry Prince

Perry Prince

  • Patent information specialist
Tamara Elmore

Tamara Elmore

  • European and Dutch Patent Attorney
  • United States Patent Agent
  • Senior Associate
More experts

News

Vaccination

“Prevention is better than cure.” That is highly applicable to the invention of vaccinations. Thanks to immunization, we can control diseases such as smallpox, polio and measles.  Across the globe, we are currently hoping that a vaccine against the coronavirus SARS-CoV-2 will be developed soon.Continue reading

COVID-19 update 6

The government measures to combat COVID-19 not only affect business operations but they could also impact you as a patent applicant or patent holder.Continue reading

COVID-19: statutory patent terms can’t simply be adjusted for no reason

The government measures to combat COVID-19 not only affect business operations but they could also impact you as a patent applicant or patent holder.Continue reading

Events

Chemport Connect – Biobased & Circular Polymers 2020

The first edition of Chemport Connect - Biobased & Circular Polymers (previously announced as the Sustainable Plastics & Materials Expo 2020) will take place digitally on 17 November 2020. Continue reading

IP Service World 2020

Holiday Inn Munich - City Centre, Hochstraße, München, Germany

Europe’s largest IP Convention & Trade Fair, the IP Service World, is a very unique event. It is the perfect mixture of a comprehensive trade fair and a top-class convention with contributions from leading experts. Continue reading

Dutch Life Sciences Conference 2020

CORPUS Congress Centre, Willem Einthovenstraat 1, 2342 BH Oegstgeest, The Netherlands

The foremost life sciences business network event in the Netherlands With more than 450 life sciences companies the Dutch Life Sciences sector has doubled in size during the last decades. Continue reading